MedTrace Logo

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NCT04897880 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-02-24

No results posted yet for this study

Summary

This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.

Conditions

  • Rhabdoid Tumor
  • Atypical Teratoid/Rhabdoid Tumor
  • Malignant Rhabdoid Tumor
  • Recurrent Brain Tumor, Childhood

Interventions

DRUG

Panobinostat

Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Secura Bio, Inc.

    collaborator INDUSTRY

  • Australian & New Zealand Children's Haematology/Oncology Group

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-09
Primary Completion
2024-05-08
Completion
2024-05-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04897880 on ClinicalTrials.gov